文献速递免疫规划

冷冻保存相关的抗原特异性产干扰素γ的CD4+ T细胞丢失可扭曲疫苗试验中的免疫原性数据:一项疟疾疫苗试验子研究的教训

Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.
PubMed 文献 · Vaccine · 2017-03-09

该子研究利用酶联免疫斑点(ELISpot)和流式细胞术细胞内细胞因子染色(ICS)评估一项II期疟疾异源初免-加强疫苗试验受试者血样的抗原特异性免疫原性,发现冻融过程可使疫苗接种后外周血单个核细胞(PBMC)中疟疾抗原特异性产干扰素γ的CD3+CD4+效应细胞群减少3-5倍,而肽反应性CD8+ T细胞及不产干扰素γ的CD4+ T细胞群相对不受影响。

要点

  • 冻融可使疫苗接种后PBMC中疟疾抗原特异性产IFNγ的CD3+CD4+效应细胞群减少3-5倍。
  • 肽反应性CD8+ T细胞及不产IFNγ的CD4+ T细胞群相对不受冻融影响。
  • 上述发现可为临床试验指南的整合与制定提供数据,以提高疫苗开发流程效率。

核心结论

  • 冷冻保存相关的抗原特异性产IFNγ的CD4+ T细胞丢失可扭曲疫苗试验中的免疫原性数据,这些发现可为临床试验指南的整合与制定提供数据,以提高疫苗开发流程效率。

研究设计与样本

  • 该研究为一项II期疟疾异源初免-加强疫苗试验的子研究,采用ELISpot和流式细胞术ICS检测受试者血样中抗原特异性免疫原性,比较冻融前后PBMC样本。

主要发现

  • 冻融过程可使疫苗接种后PBMC样本中疟疾抗原特异性产IFNγ的CD3+CD4+效应细胞群减少3-5倍。
  • 肽反应性CD8+ T细胞相对不受冻融影响,不产IFNγ的CD4+ T细胞群也相对不受影响。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ex vivo functional immunoassays such as ELISpot and intracellular cytokine staining (ICS) by flow cytometry are crucial tools in vaccine development both in the identification of novel immunogenic targets and in the immunological assessment of samples from clinical trials. Cryopreservation and subsequent thawing of PBMCs via validated processes has become a mainstay of clinical trials due to processing restrictions inherent in the disparate location and capacity of trial centres, and also in the need to standardize biological assays at central testing facilities. Logistical and financial requirement to batch process samples from multiple study timepoints are also key. We used ELISpot and ICS assays to assess antigen-specific immunogenicity in blood samples taken from subjects enrolled in a phase II malaria heterologous prime-boost vaccine trial and showed that the freeze thaw process can result in a 3-5-fold reduction of malaria antigen-specific IFNγ-producing CD3+CD4+ effector populations from PBMC samples taken post vaccination. We have also demonstrated that peptide responsive CD8+ T cells are relatively unaffected, as well as CD4+ T cell populations that do not produce IFNγ. These findings contribute to a growing body of data that could be consolidated and synthesised as guidelines for clinical trials with the aim of increasing the efficiency of vaccine development pipelines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Ford T, Wenden C, Mbekeani A, et al. Cryopreservation-related loss of antigen-specific IFNγ producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy. Vaccine. 2017. PMID: 28285985. doi:10.1016/j.vaccine.2017.02.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。